Liečba trombocytopénie

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (otvorí nové okno)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Zdroj‎: Platelets. 2022 3;33(7):1024-1030.

Označenie‎: PubMed 35040375

Identifikátor digitálneho objektu‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (otvorí nové okno)

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (otvorí nové okno)

Kantarjian HM, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A

Zdroj‎: Lancet Haematol 2018;5(3):e117-e126.

Označenie‎: PubMed 29396092

Identifikátor digitálneho objektu‎: 10.1016/S2352-3026(18)30016-4

https://www.ncbi.nlm.nih.gov/pubmed/29396092 (otvorí nové okno)

HEMATOLÓGIA

Liečba trombocytopénie

slovenčina

Liečba trombocytopénie

https://assetsnffrgf-a.akamaihd.net/assets/ct/1add6d1d93/images/syn_placeholder_sqr.png

Liečba trombocytopénie

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (otvorí nové okno)

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (otvorí nové okno)

Výbor pre styk s nemocnicami (VSN)

Informačné balíčky pre lekárov

Videá

Liečba trombocytopénie

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (otvorí nové okno)

Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (otvorí nové okno)

Výbor pre styk s nemocnicami (VSN)

Informačné balíčky pre lekárov

Videá

Vyberte si jazyk

Poslať odkaz